全文获取类型
收费全文 | 19290篇 |
免费 | 1517篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 256篇 |
儿科学 | 627篇 |
妇产科学 | 442篇 |
基础医学 | 2795篇 |
口腔科学 | 285篇 |
临床医学 | 1842篇 |
内科学 | 3623篇 |
皮肤病学 | 297篇 |
神经病学 | 1969篇 |
特种医学 | 713篇 |
外科学 | 2592篇 |
综合类 | 627篇 |
现状与发展 | 1篇 |
一般理论 | 27篇 |
预防医学 | 1522篇 |
眼科学 | 544篇 |
药学 | 1314篇 |
中国医学 | 41篇 |
肿瘤学 | 1349篇 |
出版年
2023年 | 99篇 |
2022年 | 237篇 |
2021年 | 387篇 |
2020年 | 229篇 |
2019年 | 359篇 |
2018年 | 429篇 |
2017年 | 268篇 |
2016年 | 362篇 |
2015年 | 412篇 |
2014年 | 519篇 |
2013年 | 827篇 |
2012年 | 1151篇 |
2011年 | 1077篇 |
2010年 | 673篇 |
2009年 | 636篇 |
2008年 | 1025篇 |
2007年 | 1037篇 |
2006年 | 938篇 |
2005年 | 1022篇 |
2004年 | 1028篇 |
2003年 | 957篇 |
2002年 | 867篇 |
2001年 | 346篇 |
2000年 | 353篇 |
1999年 | 331篇 |
1998年 | 241篇 |
1997年 | 189篇 |
1996年 | 182篇 |
1995年 | 180篇 |
1994年 | 139篇 |
1993年 | 159篇 |
1992年 | 244篇 |
1991年 | 219篇 |
1990年 | 236篇 |
1989年 | 236篇 |
1988年 | 219篇 |
1987年 | 194篇 |
1986年 | 203篇 |
1985年 | 220篇 |
1984年 | 172篇 |
1983年 | 136篇 |
1982年 | 149篇 |
1981年 | 157篇 |
1980年 | 129篇 |
1979年 | 116篇 |
1977年 | 100篇 |
1976年 | 117篇 |
1975年 | 102篇 |
1974年 | 130篇 |
1973年 | 95篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Fabrice Barlesi Edward B. Garon Dong-Wan Kim Enriqueta Felip Ji-Youn Han Joo-Hang Kim Myung-Ju Ahn Mary Jo Fidler Matthew A. Gubens Gilberto de Castro Veerle Surmont Qiao Li Anne C. Deitz Gregory M. Lubiniecki Roy S. Herbst 《Journal of thoracic oncology》2019,14(5):793-801
Introduction
In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over docetaxel in patients with previously treated, programmed death ligand 1–expressing (tumor proportion score ≥ 1%), advanced NSCLC. Health-related quality of life (HRQoL) results are reported here.Methods
Patients were randomized 1:1:1 to pembrolizumab 2 or 10 mg/kg every 3 weeks or docetaxel 75 mg/m2 every 3 weeks. HRQoL was assessed using European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLC) Core 30 (C30), EORTC QLQ–Lung Cancer 13 (LC13), and EuroQoL-5D. Key analyses included mean baseline-to-week-12 change in global health status (GHS)/quality of life (QoL) score, functioning and symptom domains, and time to deterioration in a QLQ-LC13 composite endpoint of cough, dyspnea, and chest pain.Results
Patient reported outcomes compliance was high across all three instruments. Pembrolizumab was associated with better QLQ-C30 GHS/QoL scores from baseline to 12 weeks than docetaxel, regardless of pembrolizumab dose or tumor proportion score status (not significant). Compared with docetaxel, fewer pembrolizumab-treated patients had “deteriorated” status and more had “improved” status in GHS/QoL. Nominally significant improvement was reported in many EORTC symptom domains with pembrolizumab, and nominally significant worsening was reported with docetaxel. Significant prolongation in true time to deterioration for the QLQ-LC13 composite endpoint emerged for pembrolizumab 10 mg/kg compared to docetaxel (nominal two-sided p = 0.03), but not for the 2-mg/kg dose.Conclusions
These findings suggest that HRQoL and symptoms are maintained or improved to a greater degree with pembrolizumab than with docetaxel in this NSCLC patient population. 相似文献3.
Peffault de Latour Rgis Huynh Lynn Ivanova Jasmina I. Totev Todor Bilginsoy Mehmet Antin Joseph Roy Anuja Duh Mei Sheng 《Annals of hematology》2020,99(4):743-752
Annals of Hematology - This study assessed treatment patterns and healthcare resource utilization (HRU) of patients with severe aplastic anemia (SAA) with insufficient response to immunosuppressive... 相似文献
4.
5.
Joe Jacob Shibhu George B. R. Suchit Roy P. U. Rajesh 《Indian journal of otolaryngology and head and neck surgery》2006,58(1):76-77
Malignancy larynx usually presents early, the common symptoms being hoarseness, pain thorat, cough and irritation of throat. An advanced malignancy is likely to be complicated by a pharyngo-cutaneous fistula. However it is an occurrence towards the end stage of the disease. Here we present a case of malignancy larynx primarily presenting as pharyngo-cutaneous fistula without any other symptoms. 相似文献
6.
Cough and paradoxical vocal fold motion 总被引:8,自引:0,他引:8
Kenneth W. Altman MD PhD C. Blake Simpson MD Milan R. Amin MD Mona Abaza MD Ron Balkissoon MD Roy R. Casiano MD 《Otolaryngology--head and neck surgery》2002,127(6):501-511
OBJECTIVES: The differential diagnosis and treatment of patients with chronic cough, paradoxical vocal fold motion, and disordered breathing can be a challenge to most practicing otolaryngologists. Tracheobronchial (ie, asthma, bronchitis, and tracheal stenosis), laryngeal (ie, vocal fold paralysis and neoplasms), and rhinologic (ie, allergies and rhinosinusitis) etiologies are commonly diagnosed and treated effectively. However, occasionally one is faced with patients who are refractory to medical treatment and have no obvious rhinologic, laryngeal or pulmonary cause. STUDY DESIGN AND SETTING: We conducted a review of the literature. METHODS: We present a thorough review of the current medical literature exploring the complex neurologic mechanisms involved in the production of cough and the relationship between gastroesophageal reflux disease, vagal neurapathy, and paradoxical vocal fold motion. RESULTS: The diagnosis and successful treatment of chronic cough can be complex. It requires a thorough understanding of the neurologic mechanisms behind cough excitation and suppression. Successful treatment strategies include aggressive management of the patient's reactive airway disease, gastroesophageal reflux disease, and, in select cases, paradoxical vocal fold motion. This may involve a well-coordinated effort among pulmonologists, otolaryngologists, gastroenterologists, and speech pathologists. CONCLUSION: Gastroesophageal reflux disease, vagal neuropathy, and paradoxical vocal fold motion are additional causes of chronic cough and disordered breathing that need to be considered, in the absence of obvious laryngotracheal and/or rhinologic pathology. A high index of suspicion is essential in making the diagnosis and formulating an effective multidisciplinary treatment plan for these patients. 相似文献
7.
8.
Dinesh Rakheja Payal Kapur Mai P. Hoang Lonnie C. Roy Michael J. Bennett 《Medical hypotheses》2005,65(6):681
Mammalian fatty acid synthase (FASE) overexpression has been shown in a number of human malignancies including colonic adenocarcinoma. Since FASE synthesizes only saturated fatty acids, we hypothesized that cancer cells have a greater proportion of long-chain saturated fatty acids. We studied and found an unequivocal increase in saturated C18 fatty acid (stearic acid) in colonic adenocarcinoma compared to adjacent normal colonic mucosa. The increase is even more striking when measured as a ratio of stearic acid to the unsaturated C18 fatty acids (oleic acid and linoleic acid). This change in fatty acid composition of the cancer cells should significantly alter their physical and biological properties. The increase in relative proportion of saturated fatty acids should make the cancer cells more susceptible to cryodamage and measurement of fatty acid composition of cancer cells may help individualize the temperature for cryotherapy. Also, the lipid alterations may affect the structure and functions of lipid rafts, which may enable the cancer cells to affect signaling mechanisms such as those involved in cell growth and apoptosis. Dietary or therapeutic interventions targeting lipid rafts may thus be an option for cancer treatment. 相似文献
9.
10.